SEC Company Response from PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Mar 18, 2010

PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: March 18, 2010 · CIK: 0001157075 · Accession: 0001099910-10-000006

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-68008

Referenced dates: March 11, 2010

Date

March 18, 2010

Author

/s/ Martin Schmieg

Form

CORRESP

Company

PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)

Letter

Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attention: Vanessa Robertson, Staff Accountant Re: Nuvilex, Inc. -- Form 8-K filed on March 9, 2010 (File No. 333-68008)

Dear Ms. Robertson:

This request is in relation to the letter dated March 11, 2010 (the “Comment Letter”), including comments from the staff of the Securities and Exchange Commission to the Form 8-K (File No. 333-68008) filed by Nuvilex, Inc., a Delaware corporation, on March 9, 2010.

We respectfully request an extension to March 26, 2010 to provide a response to the Comment Letter.

Please do not hesitate to call the undersigned at (856) 354-0707 or Jennifer A. DePalma, Esq. of O’Melveny & Myers LLP, legal counsel to Nuvilex, Inc., at (650) 473-2670, regarding this matter.

Sincerely,
/s/ Martin Schmieg

Show Raw Text

CORRESP
1
filename1.htm

    nuvilex_corresp.htm

Nuvilex, Inc.

1971 Old Cuthbert Road

Cherry Hill, New Jersey  08034

March 18, 2010

Securities and Exchange Commission

Division of Corporate Finance

Washington, D.C.  20549

Attention:  Vanessa Robertson, Staff Accountant

Re:

Nuvilex, Inc. -- Form 8-K filed on March 9, 2010 (File No. 333-68008)

Dear Ms. Robertson:

This request is in relation to the letter dated March 11, 2010 (the “Comment Letter”), including comments from the staff of the Securities and Exchange Commission to the Form 8-K (File No. 333-68008) filed by Nuvilex, Inc., a Delaware corporation, on March 9, 2010.

We respectfully request an extension to March 26, 2010 to provide a response to the Comment Letter.

Please do not hesitate to call the undersigned at (856) 354-0707 or Jennifer A. DePalma, Esq. of O’Melveny & Myers LLP, legal counsel to Nuvilex, Inc., at (650) 473-2670, regarding this matter.

Sincerely,

/s/ Martin Schmieg

Martin Schmieg

Chief Executive Officer

cc:

Jennifer A. DePalma, Esq., O’Melveny & Myers LLP

SecProbe.io